New Manufacturing Method Improves Drug Delivery of Asthma Inhalers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New Manufacturing Method Improves Drug Delivery of Asthma Inhalers


A chemical engineering team from Monash University in Australia developed a method to manufacture ultrafine particles that will improve the consistency and efficiency of drugs used in metered-dose inhalers to treat asthma, the University announced in a press release. The anti-solvent vapor precipitation method uses ethanol to dehydrate droplets, which results in ultrafine particles with a more uniform size.

 “Ultrafine uniform particles will ensure that fewer drug particles get stuck in the throat while more can reach the lower regions of the lungs,” said team leader Dr. Meng Wai Woo. “Because we can now make the small particles more uniform, it means the inhalers will work better. From a drug manufacturer’s perspective, this new approach can maintain the uniformity of the particle and yet potentially maintain commercially viable production rates.”

The team’s work results in particles smaller than a micron in diameter. These particles are much smaller than those produced by conventional dehydrating mechanisms, which are limited by the size of the atomized droplet.

Assisted by a grant from the Australian Research Council, the Monash team is now testing its method on whey to research the ultrafine particle delivery of protein-based medicines. The team is also building a demonstration unit, which will be completed later this year, to showcase the anti-solvent vapor precipitation process.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here